查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1888547

全球抗體藥物複合體（ADC）市場：市場規模、佔有率和趨勢分析（按應用、產品、有效載荷、技術、通路和地區分類），細分市場預測（2025-2033 年）

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application, By Product, By Payload, By Technology, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

抗體藥物複合體（ADC）市場摘要

2024年全球抗體藥物複合體（ADC）市場規模估計為122.6億美元，預計2033年將達到321.1億美元。

預計從 2025 年到 2033 年，該產業將以 10.49% 的複合年成長率成長。這一成長主要受癌症患者數量增加以及對療效高、全身毒性小的標靶治療的需求不斷成長的推動。

抗體藥物複合體（ADC）市場正經歷顯著成長，這主要得益於標靶治療的進步、臨床試驗數量的增加以及製藥公司的策略投資。持續的研發活動為此擴張提供了支持，而標靶治療和精準醫療的進步也使ADC成為腫瘤治療領域更具吸引力的選擇。全球各種癌症發生率的不斷上升，推動了對高效且副作用更少的治療方法的需求。 ADC透過將強效細胞毒性藥物直接遞送至癌細胞，同時保護健康組織，從而滿足了這一需求，並改善了患者的治療效果。臨床試驗數量的增加和監管核准的增多，反映了製藥公司對這一新興治療領域的投資意願。

例如，2025年6月，針對TROP2蛋白的抗體藥物偶聯物Datroway（達托泊單抗德魯西替康）在美國核准，用於治療先前接受過治療的進行性非小細胞肺癌成人患者。此外，2025年2月，FDA核准Datroway用於治療先前接受過內分泌治療和化療的不可切除或轉移性荷爾蒙受體陽性、HER2陰性乳癌成人患者。同樣，2025年4月，葛蘭素史克（GSK）的抗體藥物複合體Blenrep獲得英國監管部門核准，可與其他藥物聯合治療用於治療至少接受過一種既往治療的多發性骨髓瘤成人患者。這些進展凸顯了抗體藥物複合體（ADC）療法的持續成長和已證實的療效。

目錄

第1章 分析方法和範圍

第2章執行摘要

第3章抗體藥物複合體（ADC）市場：影響因素、趨勢和範圍

  • 市場聯動展望
  • 市場動態
  • 商業環境分析
    • 產業分析：波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章抗體藥物複合體（ADC）市場：按應用領域分類的業務分析

  • 按應用領域分類的市場佔有率（2024 年和 2033 年）
  • 按應用領域分類的市場規模預測和趨勢分析（2021-2033）
  • 乳癌
  • 血癌
  • 淋巴瘤
  • 白血病
  • 尿路上皮癌
  • 卵巢癌
  • 其他

第5章抗體藥物複合體（ADC）市場：按產品分類的業務分析

  • 按產品分類的市場佔有率（2024 年和 2033 年）
  • 市場規模預測及趨勢分析：依產品分類（2021-2033 年）
  • 門頭
  • 恩赫茲
  • 托羅德爾比
  • ADCETRIS
  • 聚維
  • 其他

第6章抗體藥物複合體市場：以有效載荷進行業務分析

  • 按有效載荷分類的市場佔有率（2024 年和 2033 年）
  • 按有效載荷分類的市場規模預測和趨勢分析（2021-2033 年）
  • 奧瑞他汀
  • 美登素類
  • 卡利奇黴素衍生物
  • 拓樸異構酶I抑制劑
  • 吡咯並苯二氮平（PBD）二聚體
  • 其他

第7章抗體藥物複合體（ADC）市場：按技術分類的業務分析

  • 按技術分類的市場佔有率（2024 年和 2033 年）
  • 按技術分類的市場規模預測和趨勢分析（2021-2033）
  • 可裂解連接子
  • 不可切割的連接子
  • 其他

第8章抗體藥物複合體(ADC) 市場：按分銷管道分類的業務分析

  • 按分銷管道分類的市場佔有率（2024 年和 2033 年）
  • 按分銷管道分類的市場規模預測和趨勢分析（2021-2033）
  • 醫院藥房
  • 專科藥房
  • 其他

第9章：抗體藥物複合體（ADC）市場：區域預測與趨勢分析

  • 按地區分類的市場佔有率分析（2024 年和 2033 年）
  • 市場概覽：按地區
  • 市場規模預測及趨勢分析（2021-2033）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第10章 競爭格局

  • 參與企業概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/列表
    • Seagen, Inc.
    • Takeda Pharmaceutical Company Ltd.
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • Gilead Sciences, Inc.
    • Daiichi Sankyo Company Ltd.
    • antibody drug conjugates Therapeutics SA
Product Code: GVR-2-68038-741-4

Antibody Drug Conjugates Market Summary

The global antibody drug conjugates market size was estimated at USD 12.26 billion in 2024 and is projected to reach USD 32.11 billion by 2033, growing at a CAGR of 10.49% from 2025 to 2033. This growth is primarily driven by the increasing prevalence of cancer and the growing demand for targeted therapies that offer greater efficacy with reduced systemic toxicity.

The antibody-drug conjugates (ADC) market is experiencing significant growth, driven by advancements in targeted therapies, increasing clinical trials, and strategic investments by pharmaceutical companies. Ongoing research and development activities support this expansion, with ongoing advancements in targeted therapy and precision medicine increasing the appeal of ADCs as a preferred treatment option in oncology. The rising global incidence of various cancer types has created a demand for therapies that offer high efficacy with fewer adverse effects. ADCs address this need by delivering potent cytotoxic agents directly to cancer cells while sparing healthy tissues, thereby improving patient outcomes. The increasing number of clinical trials and regulatory approvals reflects the commitment of pharmaceutical companies to invest in this novel treatment class.

For instance, in June 2025, the U.S. approved Datroway (datopotamab deruxtecan), an ADC targeting the TROP 2 protein, for the treatment of advanced non-small cell lung cancer in adults who had previously undergone treatment. Additionally, in February 2025, the FDA approved Datroway for the treatment of unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer in adults who had undergone prior endocrine-based therapy and chemotherapy. Similarly, in April 2025, GSK received UK regulatory approval for Blenrep, an ADC for the treatment of adults with multiple myeloma in combination with another medication after at least one prior therapy. These developments highlight the continued growth and validation of ADC therapies.

Global Antibody Drug Conjugates Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antibody drug conjugates market report based on application, product, payload, technology, distribution channel, and region:

  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Breast Cancer
  • Blood Cancer
    • Lymphoma
    • Leukemia
  • Urothelial Carcinoma
  • Ovarian Cancer
  • Others
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Kadcyla (ado-trastuzumab emtansine)
  • Enhertu (trastuzumab deruxtecan)
  • Trodelvy (sacituzumab govitecan)
  • Adcetris (brentuximab vedotin)
  • Polivy (polatuzumab vedotin)
  • Others (Padcev, Tivdak, Elahere, Zynlonta, Mylotarg, Besponsa)
  • Payload Outlook (Revenue, USD Million, 2021 - 2033)
  • Auristatins (MMAE, MMAF)
  • Maytansinoids (DM1, DM4)
  • Calicheamicin Derivatives
  • Topoisomerase I Inhibitors (SN-38, DXd)
  • Pyrrolobenzodiazepine (PBD) Dimers
  • Others
  • TechnologyOutlook (Revenue, USD Million, 2021 - 2033)
  • Cleavable Linker
  • Non-Cleavable Linker
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacy
  • Specialty Pharmacy
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Product
    • 1.2.3. Payload
    • 1.2.4. Technology
    • 1.2.5. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Antibody Drug Conjugates Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Antibody Drug Conjugates Market: Application Business Analysis

  • 4.1. Application Market Share, 2024 & 2033
  • 4.2. Application Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 4.4. Breast Cancer
    • 4.4.1. Breast Cancer Market, 2021 - 2033 (USD Million)
  • 4.5. Blood Cancer
    • 4.5.1. Blood Cancer Market, 2021 - 2033 (USD Million)
  • 4.6. Lymphoma
    • 4.6.1. Lymphoma Market, 2021 - 2033 (USD Million)
  • 4.7. Leukemia
    • 4.7.1. Leukemia Market, 2021 - 2033 (USD Million)
  • 4.8. Urothelial Carcinoma
    • 4.8.1. Urothelial Carcinoma Market, 2021 - 2033 (USD Million)
  • 4.9. Ovarian Cancer
    • 4.9.1. Ovarian Cancer Market, 2021 - 2033 (USD Million)
  • 4.10. Others
    • 4.10.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Antibody Drug Conjugates Market: Product Business Analysis

  • 5.1. Product Market Share, 2024 & 2033
  • 5.2. Product Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 5.4. Kadcyla
    • 5.4.1. Kadcyla Market, 2021 - 2033 (USD Million)
  • 5.5. Enhertu
    • 5.5.1. Enhertu Market, 2021 - 2033 (USD Million)
  • 5.6. Trodelvy
    • 5.6.1. Trodelvy Market, 2021 - 2033 (USD Million)
  • 5.7. Adcetris
    • 5.7.1. Adcetris Market, 2021 - 2033 (USD Million)
  • 5.8. Polivy
    • 5.8.1. Polivy Market, 2021 - 2033 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Antibody Drug Conjugates Market: Payload Business Analysis

  • 6.1. Payload Market Share, 2024 & 2033
  • 6.2. Payload Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by payload, 2021 to 2033 (USD Million)
  • 6.4. Auristatins
    • 6.4.1. Auristatins Market, 2021 - 2033 (USD Million)
  • 6.5. Maytansinoids
    • 6.5.1. Maytansinoids Market, 2021 - 2033 (USD Million)
  • 6.6. Calicheamicin Derivatives
    • 6.6.1. Calicheamicin Derivatives Market, 2021 - 2033 (USD Million)
  • 6.7. Topoisomerase I Inhibitors
    • 6.7.1. Topoisomerase I Inhibitors Market, 2021 - 2033 (USD Million)
  • 6.8. Pyrrolobenzodiazepine (PBD) Dimers
    • 6.8.1. Pyrrolobenzodiazepine (PBD) Dimers Market, 2021 - 2033 (USD Million)
  • 6.9. Others
    • 6.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Antibody Drug Conjugates Market: Technology Business Analysis

  • 7.1. Technology Market Share, 2024 & 2033
  • 7.2. Technology Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by technology, 2021 to 2033 (USD Million)
  • 7.4. Cleavable Linker
    • 7.4.1. Cleavable Linker Market, 2021 - 2033 (USD Million)
  • 7.5. Non- cleavable Linker
    • 7.5.1. Non- cleavable Linker Market, 2021 - 2033 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Antibody Drug Conjugates Market: Distribution Channel Business Analysis

  • 8.1. Distribution Channel Market Share, 2024 & 2033
  • 8.2. Distribution Channel Segment Dashboard
  • 8.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
  • 8.4. Hospital Pharmacy
    • 8.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
  • 8.5. Specialty Pharmacy
    • 8.5.1. Specialty Pharmacy Market, 2021 - 2033 (USD Million)
  • 8.6. Others
    • 8.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 9. Antibody Drug Conjugates Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Share Analysis, 2024 & 2033
  • 9.2. Regional Market Dashboard
  • 9.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 9.4. North America
    • 9.4.1. North America Antibody Drug Conjugates Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 9.4.2. U.S.
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Target Disease Prevalence
      • 9.4.2.3. Regulatory Framework
      • 9.4.2.4. Reimbursement Framework
      • 9.4.2.5. U.S. Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.3. Canada
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Target Disease Prevalence
      • 9.4.3.3. Regulatory Framework
      • 9.4.3.4. Reimbursement Framework
      • 9.4.3.5. U.S. Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.4. Mexico
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Target Disease Prevalence
      • 9.4.4.3. Regulatory Framework
      • 9.4.4.4. Reimbursement Framework
      • 9.4.4.5. Mexico Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. Europe
    • 9.5.1. Europe Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.2. UK
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Target Disease Prevalence
      • 9.5.2.3. Regulatory Framework
      • 9.5.2.4. Reimbursement Framework
      • 9.5.2.5. Uk Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.3. Germany
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Target Disease Prevalence
      • 9.5.3.3. Regulatory Framework
      • 9.5.3.4. Reimbursement Framework
      • 9.5.3.5. Germany Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.4. France
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Target Disease Prevalence
      • 9.5.4.3. Regulatory Framework
      • 9.5.4.4. Reimbursement Framework
      • 9.5.4.5. France Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.5. Italy
      • 9.5.5.1. Key Country Dynamics
      • 9.5.5.2. Target Disease Prevalence
      • 9.5.5.3. Regulatory Framework
      • 9.5.5.4. Reimbursement Framework
      • 9.5.5.5. Italy Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.6. Spain
      • 9.5.6.1. Key Country Dynamics
      • 9.5.6.2. Target Disease Prevalence
      • 9.5.6.3. Regulatory Framework
      • 9.5.6.4. Reimbursement Framework
      • 9.5.6.5. Spain Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.7. Denmark
      • 9.5.7.1. Key Country Dynamics
      • 9.5.7.2. Target Disease Prevalence
      • 9.5.7.3. Regulatory Framework
      • 9.5.7.4. Reimbursement Framework
      • 9.5.7.5. Denmark Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.8. Sweden
      • 9.5.8.1. Key Country Dynamics
      • 9.5.8.2. Target Disease Prevalence
      • 9.5.8.3. Regulatory Framework
      • 9.5.8.4. Reimbursement Framework
      • 9.5.8.5. Sweden Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.9. Norway
      • 9.5.9.1. Key Country Dynamics
      • 9.5.9.2. Target Disease Prevalence
      • 9.5.9.3. Regulatory Framework
      • 9.5.9.4. Reimbursement Framework
      • 9.5.9.5. Norway Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Asia Pacific
    • 9.6.1. Asia Pacific Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.2. Japan
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Target Disease Prevalence
      • 9.6.2.3. Regulatory Framework
      • 9.6.2.4. Reimbursement Framework
      • 9.6.2.5. Japan Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.3. China
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Target Disease Prevalence
      • 9.6.3.3. Regulatory Framework
      • 9.6.3.4. Reimbursement Framework
      • 9.6.3.5. China Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.4. India
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Target Disease Prevalence
      • 9.6.4.3. Regulatory Framework
      • 9.6.4.4. Reimbursement Framework
      • 9.6.4.5. India Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.5. Australia
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Target Disease Prevalence
      • 9.6.5.3. Regulatory Framework
      • 9.6.5.4. Reimbursement Framework
      • 9.6.5.5. Australia Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.6. South Korea
      • 9.6.6.1. Key Country Dynamics
      • 9.6.6.2. Target Disease Prevalence
      • 9.6.6.3. Regulatory Framework
      • 9.6.6.4. Reimbursement Framework
      • 9.6.6.5. South Korea Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.7. Thailand
      • 9.6.7.1. Key Country Dynamics
      • 9.6.7.2. Target Disease Prevalence
      • 9.6.7.3. Regulatory Framework
      • 9.6.7.4. Reimbursement Framework
      • 9.6.7.5. Thailand Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7. Latin America
    • 9.7.1. Latin America Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.7.2. Brazil
      • 9.7.2.1. Key Country Dynamics
      • 9.7.2.2. Target Disease Prevalence
      • 9.7.2.3. Regulatory Framework
      • 9.7.2.4. Reimbursement Framework
      • 9.7.2.5. Japan Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.7.3. Argentina
      • 9.7.3.1. Key Country Dynamics
      • 9.7.3.2. Target Disease Prevalence
      • 9.7.3.3. Regulatory Framework
      • 9.7.3.4. Reimbursement Framework
      • 9.7.3.5. China Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8. Middle East and Africa
    • 9.8.1. Middle East and Africa Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.2. South Africa
      • 9.8.2.1. Key Country Dynamics
      • 9.8.2.2. Target Disease Prevalence
      • 9.8.2.3. Regulatory Framework
      • 9.8.2.4. Reimbursement Framework
      • 9.8.2.5. South Africa Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.3. Saudi Arabia
      • 9.8.3.1. Key Country Dynamics
      • 9.8.3.2. Target Disease Prevalence
      • 9.8.3.3. Regulatory Framework
      • 9.8.3.4. Reimbursement Framework
      • 9.8.3.5. Saudi Arabia Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.4. UAE
      • 9.8.4.1. Key Country Dynamics
      • 9.8.4.2. Target Disease Prevalence
      • 9.8.4.3. Regulatory Framework
      • 9.8.4.4. Reimbursement Framework
      • 9.8.4.5. UAE Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.5. Kuwait
      • 9.8.5.1. Key Country Dynamics
      • 9.8.5.2. Target Disease Prevalence
      • 9.8.5.3. Regulatory Framework
      • 9.8.5.4. Reimbursement Framework
      • 9.8.5.5. Kuwait Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Participant Overview
  • 10.2. Company Market Position Analysis
  • 10.3. Company Categorization
  • 10.4. Strategy Mapping
  • 10.5. Company Profiles/Listing
    • 10.5.1. Seagen, Inc.
      • 10.5.1.1. Overview
      • 10.5.1.2. Financial Performance
      • 10.5.1.3. Application Benchmarking
      • 10.5.1.4. Strategic Initiatives
    • 10.5.2. Takeda Pharmaceutical Company Ltd.
      • 10.5.2.1. Overview
      • 10.5.2.2. Financial Performance
      • 10.5.2.3. Application Benchmarking
      • 10.5.2.4. Strategic Initiatives
    • 10.5.3. AstraZeneca
      • 10.5.3.1. Overview
      • 10.5.3.2. Financial Performance
      • 10.5.3.3. Application Benchmarking
      • 10.5.3.4. Strategic Initiatives
    • 10.5.4. F. Hoffmann-La Roche Ltd.
      • 10.5.4.1. Overview
      • 10.5.4.2. Financial Performance
      • 10.5.4.3. Application Benchmarking
      • 10.5.4.4. Strategic Initiatives
    • 10.5.5. Pfizer, Inc.
      • 10.5.5.1. Overview
      • 10.5.5.2. Financial Performance
      • 10.5.5.3. Application Benchmarking
      • 10.5.5.4. Strategic Initiatives
    • 10.5.6. Gilead Sciences, Inc.
      • 10.5.6.1. Overview
      • 10.5.6.2. Financial Performance
      • 10.5.6.3. Application Benchmarking
      • 10.5.6.4. Strategic Initiatives
    • 10.5.7. Daiichi Sankyo Company Ltd.
      • 10.5.7.1. Overview
      • 10.5.7.2. Financial Performance
      • 10.5.7.3. Application Benchmarking
      • 10.5.7.4. Strategic Initiatives
    • 10.5.8. antibody drug conjugates Therapeutics SA
      • 10.5.8.1. Overview
      • 10.5.8.2. Financial Performance
      • 10.5.8.3. Application Benchmarking
      • 10.5.8.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global antibody drug conjugates market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 5 Global antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 6 Global antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 7 Global antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 8 Global antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9 North America antibody drug conjugates market, by country, 2021 - 2033 (USD Million)
  • Table 10 North America antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 11 North America antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 12 North America antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 13 North America antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 14 North America antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15 U.S. antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 16 U.S. antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 17 U.S. antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 18 U.S. antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 19 U.S. antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Canada antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 21 Canada antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 22 Canada antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 23 Canada antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 24 Canada antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 25 Mexico antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 26 Mexico antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 27 Mexico antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 28 Mexico antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 29 Mexico antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 Europe antibody drug conjugates market, by country, 2021 - 2033 (USD Million)
  • Table 31 Europe antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 32 Europe antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 33 Europe antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 34 Europe antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 35 Europe antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36 UK antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 37 UK antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 38 UK antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 39 UK antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 40 UK antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41 Germany antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 42 Germany antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 43 Germany antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 44 Germany antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 45 Germany antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 46 France antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 47 France antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 48 France antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 49 France antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 50 France antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 51 Italy antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 52 Italy antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 53 Italy antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 54 Italy antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 55 Italy antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56 Spain antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 57 Spain antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 58 Spain antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 59 Spain antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 60 Spain antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Norway antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 62 Norway antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 63 Norway antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 64 Norway antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 65 Norway antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 66 Denmark antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 67 Denmark antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 68 Denmark antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 69 Denmark antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 70 Denmark antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 71 Sweden antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 72 Sweden antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 73 Sweden antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 74 Sweden antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 75 Sweden antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 76 Asia Pacific antibody drug conjugates market, by country, 2021 - 2033 (USD Million)
  • Table 77 Asia Pacific antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 78 Asia Pacific antibody drug conjugates market, by product, 2021 - 2033 (USD
  • Table 79 Asia Pacific antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 80 Asia Pacific antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 81 Asia Pacific antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 82 Million)
  • Table 83 Japan antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 84 Japan antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 85 Japan antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 86 Japan antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 87 Japan antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 88 China antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 89 China antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 90 China antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 91 China antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 92 China antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 93 India antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 94 India antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 95 India antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 96 India antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 97 India antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 98 Australia antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 99 Australia antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 100 Australia antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 101 Australia antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 102 Australia antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 103 South Korea antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 104 South Korea antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 105 South Korea antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 106 South Korea antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 107 South Korea antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 108 Thailand antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 109 Thailand antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 110 Thailand antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 111 Thailand antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 112 Thailand antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 113 Latin America antibody drug conjugates market, by country, 2021 - 2033 (USD Million)
  • Table 114 Latin America antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 115 Latin America antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 116 Latin America antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 117 Latin America antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 118 Latin America antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 119 Brazil antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 120 Brazil antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 121 Brazil antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 122 Brazil antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 123 Brazil antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 124 Brazil antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 125 Argentina antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 126 Argentina antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 127 Argentina antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 128 Argentina antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 129 Argentina antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 130 Middle East & Africa Antibody drug conjugates market, by country, 2021 - 2033 (USD Million)
  • Table 131 Middle East & Africa antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 132 Middle East & Africa antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 133 Middle East & Africa antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 134 Middle East & Africa antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 135 Middle East & Africa antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 136 South Africa antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 137 South Africa antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 138 South Africa antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 139 South Africa antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 140 South Africa antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 141 Saudi Arabia antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 142 Saudi Arabia antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 143 Saudi Arabia antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 144 Saudi Arabia antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 145 Saudi Arabia antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 146 UAE antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 147 UAE antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 148 UAE antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 149 UAE antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 150 UAE antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 151 Kuwait antibody drug conjugates market, by application, 2021 - 2033 (USD Million)
  • Table 152 Kuwait antibody drug conjugates market, by product, 2021 - 2033 (USD Million)
  • Table 153 Kuwait antibody drug conjugates market, by payload, 2021 - 2033 (USD Million)
  • Table 154 Kuwait antibody drug conjugates market, by technology, 2021 - 2033 (USD Million)
  • Table 155 Kuwait antibody drug conjugates market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Antibody drug conjugates market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Antibody drug conjugates market dynamics
  • Fig. 12 Antibody drug conjugates market: Porter's five forces analysis
  • Fig. 13 Antibody drug conjugates market: PESTLE analysis
  • Fig. 14 Application market, 2021 - 2033 (USD Million)
  • Fig. 15 Breast cancer market, 2021 - 2033 (USD Million)
  • Fig. 16 Blood cancer market, 2021 - 2033 (USD Million)
  • Fig. 17 Leukemia market, 2021 - 2033 (USD Million)
  • Fig. 18 Lymphoma market, 2021 - 2033 (USD Million)
  • Fig. 19 Urothelial carcinoma market, 2021 - 2033 (USD Million)
  • Fig. 20 Ovarian Cancer market, 2021 - 2033 (USD Million)
  • Fig. 21 Other cancer market, 2021 - 2033 (USD Million)
  • Fig. 22 Product market, 2021 - 2033 (USD Million)
  • Fig. 23 Kadcyla market, 2021 - 2033 (USD Million)
  • Fig. 24 Enhertu market, 2021 - 2033 (USD Million)
  • Fig. 25 Trodelvy market, 2021 - 2033 (USD Million)
  • Fig. 26 Adcetris market, 2021 - 2033 (USD Million)
  • Fig. 27 Polivy market, 2021 - 2033 (USD Million)
  • Fig. 28 Others market, 2021 - 2033 (USD Million)
  • Fig. 29 Payload market, 2021 - 2033 (USD Million)
  • Fig. 30 Auristatins market, 2021 - 2033 (USD Million)
  • Fig. 31 Maytansinoids market, 2021 - 2033 (USD Million)
  • Fig. 32 Calicheamicin Derivatives market, 2021 - 2033 (USD Million)
  • Fig. 33 Topoisomerase I Inhibitors market, 2021 - 2033 (USD Million)
  • Fig. 34 Pyrrolobenzodiazepine (PBD) Dimers market, 2021 - 2033 (USD Million)
  • Fig. 35 Others market, 2021 - 2033 (USD Million)
  • Fig. 36 Technology market, 2021 - 2033 (USD Million)
  • Fig. 37 Technology type market, 2021 - 2033 (USD Million)
  • Fig. 38 Cleavable Linker market, 2021 - 2033 (USD Million)
  • Fig. 39 Non- cleavable Linker market, 2021 - 2033 (USD Million)
  • Fig. 40 Others market, 2021 - 2033 (USD Million)
  • Fig. 41 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 42 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 43 Hospital Pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 44 Specialty Pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 45 Others market, 2021 - 2033 (USD Million)
  • Fig. 46 Antibody drug conjugates market revenue, by region
  • Fig. 47 Regional marketplace: Key takeaways
  • Fig. 48 North America antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 49 U.S. country dynamics
  • Fig. 50 U.S. antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 51 Canada country dynamics
  • Fig. 52 Canada antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 53 Mexico country dynamics
  • Fig. 54 Mexico antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 55 Europe antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 56 UK country dynamics
  • Fig. 57 UK antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 58 Germany country dynamics
  • Fig. 59 Germany antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 60 France country dynamics
  • Fig. 61 France antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 62 Italy country dynamics
  • Fig. 63 Italy antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 64 Spain country dynamics
  • Fig. 65 Spain antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 66 Norway country dynamics
  • Fig. 67 Norway antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 68 Sweden country dynamics
  • Fig. 69 Sweden antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 70 Denmark country dynamics
  • Fig. 71 Denmark antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 72 Asia Pacific antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 73 Japan country dynamics
  • Fig. 74 Japan antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 75 China country dynamics
  • Fig. 76 China antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 77 India country dynamics
  • Fig. 78 India antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 79 Australia country dynamics
  • Fig. 80 Australia antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 81 South Korea country dynamics
  • Fig. 82 South Korea antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 83 Thailand country dynamics
  • Fig. 84 Thailand antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 85 Latin America antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 86 Brazil country dynamics
  • Fig. 87 Brazil antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 88 Argentina country dynamics
  • Fig. 89 Argentina antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 90 MEA antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 91 South Africa country dynamics
  • Fig. 92 South Africa antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 93 Saudi Arabia country dynamics
  • Fig. 94 Saudi Arabia antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 95 UAE country dynamics
  • Fig. 96 UAE antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 97 Kuwait country dynamics
  • Fig. 98 Kuwait antibody drug conjugates market, 2021 - 2033 (USD Million)
  • Fig. 99 Company categorization
  • Fig. 100 Company market position analysis
  • Fig. 101 Strategic framework